Friday, May 01, 2026

by Matt Baker, Physicians Office Resource

From Retrospective Data to Real-Time Decision-Making

For decades, hemoglobin A1c (HbA1c) has served as the cornerstone of diabetes diagnosis and longitudinal management. Its ability to reflect average glycemic control over approximately three months makes it indispensable in primary care. Yet despite its clinical value, the traditional laboratory-based A1c workflow has long been constrained by a fundamental limitation: time. When results are delayed by days, the opportunity to act in the moment—when the patient is present, engaged, and receptive—is lost.

In most primary care settings, A1c testing has historically been a retrospective tool. Blood is drawn during the visit, sent to a centralized laboratory, and results are returned sometime later. Clinicians must then decide whether to call the patient, wait until the next visit, or attempt to make treatment changes without the benefit of face-to-face discussion. 

Each of these approaches introduces friction, and often, inaction. This delay contributes to what is widely recognized as clinical inertia—the failure to initiate or intensify therapy when indicated. 

Point-of-care (POC) A1c testing represents a meaningful departure from this paradigm. By bringing accurate, rapid testing directly into the exam room, clinicians can obtain actionable data within minutes and make informed decisions during the same encounter. 

This shift transforms A1c from a passive marker into an active driver of care, enabling a more responsive, patient-centered model of diabetes management.

The Clinical Role of A1c: Why Timing Changes Everything 

HbA1c remains one of the most reliable and widely accepted measures of long-term glycemic control. Unlike fasting plasma glucose, it does not require patient preparation and is less influenced by short-term fluctuations due to stress, illness, or dietary variability. Because it reflects glycation over the lifespan of red blood cells, it provides a stable, integrated picture of glycemic exposure over roughly 8–12 weeks. 

However, the value of A1c is not solely in its accuracy—it lies in its timing. A precise measurement that arrives too late to influence care decisions is inherently limited in its clinical utility. In chronic diseases such as diabetes, where management depends on iterative adjustments to therapy, even small delays can compound over time. A missed opportunity to intensify treatment today may translate into months of suboptimal glycemic control, increasing the risk of both microvascular and macrovascular complications. 

When A1c results are available during the visit, their meaning changes. The number is no longer a retrospective summary; it becomes a real-time signal that can guide immediate action. This temporal shift—from delayed to immediate—fundamentally alters the way clinicians and patients interact with the data.

Point-of-Care A1c Testing: A Practical Evolution in Primary Care 

Point-of-care A1c testing has matured significantly over the past decade, evolving from a niche capability into a practical, scalable solution for primary care practices. Modern systems require only a small fingerstick sample and deliver results in a matter of minutes, often within the timeframe of a standard office visit. These devices are typically CLIA-waived, meaning they are designed for ease of use and require minimal training for clinical staff. 

What distinguishes current-generation POC devices is not just their speed, but their reliability. Most systems are standardized to National Glycohemoglobin Standardization Program (NGSP) and International Federation of Clinical Chemistry (IFCC) reference methods, ensuring that results are consistent with those obtained from central laboratories. This alignment has been critical in driving adoption, as clinicians can trust that treatment decisions based on POC results are grounded in accurate data. 

Equally important is the integration of these devices into clinical workflows. Rather than disrupting the visit, A1c testing can be performed during rooming or early in the encounter, with results available by the time the physician begins the clinical discussion. This seamless integration allows practices to maintain efficiency while enhancing the quality of care delivered.

Real-Time Clinical Decision-Making: Closing the Loop 

The most immediate and tangible benefit of exam-room A1c testing is the ability to make decisions in real time. Instead of deferring action until lab results return, clinicians can evaluate glycemic control, discuss contributing factors, and adjust treatment plans within a single visit. 

This capability has profound implications for therapy management. When an elevated A1c is identified, clinicians can initiate or intensify pharmacologic therapy on the spot, whether that involves adding a second oral agent, introducing a GLP-1 receptor agonist, or initiating basal insulin. Conversely, when A1c levels have improved, therapy can be de-escalated appropriately, reducing the risk of hypoglycemia and medication burden. The immediacy of these decisions ensures that treatment is aligned with current clinical status rather than outdated data. 

Beyond medication adjustments, real-time A1c testing provides an opportunity to address adherence and lifestyle factors in a meaningful way. When patients and clinicians review the result together, the conversation naturally shifts toward understanding the drivers behind the number. This might include medication adherence, dietary patterns, physical activity, or psychosocial barriers. Addressing these factors in the moment increases the likelihood of meaningful change. 

Perhaps most importantly, point-of-care testing reduces clinical inertia. By eliminating delays, it removes one of the primary barriers to timely intervention. Over time, this can lead to more consistent achievement of glycemic targets and improved long-term outcomes.

Patient Engagement: Turning Data into Motivation 

While the clinical advantages of real-time A1c testing are significant, its impact on patient engagement may be even more transformative. Diabetes management is inherently behavioral, requiring sustained lifestyle changes and adherence to complex treatment regimens. Data alone is rarely sufficient to drive change; it must be presented in a way that is immediate, relevant, and actionable. 

When patients receive their A1c result during the visit, the number becomes tangible. It is no longer an abstract value communicated days later via a phone call or patient portal. Instead, it is part of a live conversation, contextualized within the patient’s recent behaviors and experiences. This immediacy strengthens the connection between actions and outcomes, making the consequences of daily choices more apparent. 

Real-time feedback also facilitates shared decision-making. Rather than prescribing changes in a top-down manner, clinicians can engage patients in a collaborative discussion about next steps. For example, a patient whose A1c has improved may be encouraged to reflect on what strategies have been effective, reinforcing positive behaviors. Conversely, a patient with worsening control can be invited to identify barriers and co-develop solutions. This collaborative approach fosters a sense of ownership and accountability, which is critical for long-term success. 

In addition, immediate results can enhance adherence. When treatment changes are made in direct response to current data and explained in context, patients are more likely to understand and accept the rationale behind those changes. This clarity reduces confusion and increases the likelihood that patients will follow through with recommendations.

Advancements in Point-of-Care Technology 

The rapid evolution of point-of-care A1c testing technology has been a key driver of its adoption in primary care. Modern analyzers are designed to balance accuracy, speed, and usability, making them well-suited for busy clinical environments. 

Benchtop analyzers such as the Afinion 2 Analyzer and the DCA Vantage Analyzer have become mainstays in many practices. These systems are capable of delivering results in just a few minutes and often support multiple assays, including urine albumin-to-creatinine ratio (ACR), allowing clinicians to assess both glycemic control and early signs of nephropathy during the same visit. Their ability to interface with electronic health record systems further enhances their utility, enabling automatic documentation and reducing the risk of transcription errors. 

In parallel, portable and handheld devices have expanded the reach of A1c testing beyond traditional clinic settings. Systems like the A1CNow Plus System are compact, easy to use, and well-suited for mobile clinics, home visits, and community health programs. These devices maintain a high level of accuracy while offering greater flexibility in how and where care is delivered. 

Underlying these platforms are increasingly sophisticated analytical technologies. Techniques such as boronate affinity and fluorescence-based detection have improved resistance to interference from hemoglobin variants, enhancing reliability across diverse patient populations. Emerging microfluidic technologies are further refining precision while reducing sample volume and processing time, bringing point-of-care testing ever closer to laboratory-grade performance.

Extending Care Beyond the Clinic: At-Home A1c Testing 

The evolution of A1c testing is not limited to the clinical setting. Advances in technology have enabled the development of at-home A1c testing kits, which allow patients to measure their levels independently. 

These systems typically use a fingerstick sample and provide results within minutes, offering a convenient way for patients to monitor trends between office visits. While they are not intended to replace clinician-directed testing, they can serve as a valuable adjunct, particularly in the context of remote patient monitoring or telehealth. 

At-home testing empowers patients by giving them more frequent insight into their glycemic control. This can reinforce adherence to treatment plans and encourage proactive engagement with lifestyle modifications. When integrated into a broader care model that includes clinician oversight and digital health tools, at-home A1c testing can support a more continuous, rather than episodic, approach to diabetes management.

Integration with Digital Health Ecosystems 

As healthcare continues to embrace digital transformation, A1c testing is increasingly being integrated into connected care ecosystems. Many modern point-of-care devices are capable of interfacing directly with electronic health records, allowing results to be uploaded automatically and made immediately available to the care team. This integration supports more efficient documentation, facilitates quality reporting, and enables population health management. 

In addition, A1c data can be combined with other sources of information, such as continuous glucose monitoring (CGM) and remote patient monitoring platforms. While A1c provides a long-term view of glycemic control, CGM offers granular, real-time insights into glucose variability and time-in-range. Together, these tools provide a more comprehensive picture of a patient’s metabolic status, allowing for more nuanced and individualized care. 

Telehealth has further expanded the relevance of real-time diagnostics. In hybrid care models, patients may complete A1c testing at home or in a local setting, with results transmitted to their primary care provider for review during a virtual visit. This approach maintains the immediacy of decision-making while reducing the need for in-person visits, improving access and convenience.

Clinical Considerations and Implementation 

Despite its many advantages, the adoption of point-of-care A1c testing requires thoughtful implementation. Practices must consider factors such as staff training, workflow integration, and quality control. Although CLIA-waived devices are designed for ease of use, ensuring consistent technique and adherence to calibration protocols is essential for maintaining accuracy. 

There are also clinical considerations to keep in mind. While modern devices are highly reliable, certain conditions—such as hemoglobinopathies, anemia, or recent transfusions—can affect A1c measurements. Clinicians should remain vigilant for situations in which alternative markers of glycemic control may be more appropriate. 

Cost is another factor, particularly for smaller practices. However, when viewed in the context of improved efficiency, reduced follow-up visits, and better clinical outcomes, point-of-care testing often represents a favorable investment. In value-based care models, the ability to achieve glycemic targets and reduce complications can translate into meaningful financial benefits.

Alignment with Value-Based Care 

The shift toward value-based care has placed greater emphasis on outcomes, quality metrics, and patient satisfaction. Diabetes management is a central focus of many of these initiatives, with measures such as A1c control serving as key performance indicators. 

Point-of-care A1c testing aligns naturally with these goals. By enabling immediate intervention, it increases the likelihood that patients will achieve and maintain target A1c levels. This, in turn, reduces the risk of complications such as retinopathy, nephropathy, and cardiovascular disease. Improved outcomes not only benefit patients but also support practice performance under value-based reimbursement models. 

Furthermore, the enhanced patient experience associated with real-time testing can improve satisfaction and retention. Patients appreciate the efficiency of receiving results during the visit and the opportunity to engage in meaningful discussions about their care. 

These factors contribute to stronger patient-provider relationships and better long-term engagement.

The Future of A1c Testing in Primary Care 

Looking ahead, the role of A1c testing in primary care is likely to continue evolving. Advances in technology are expected to yield even faster, smaller, and more accurate devices, further reducing barriers to adoption. At the same time, the integration of artificial intelligence and predictive analytics may enhance the clinical utility of A1c data, providing clinicians with decision support based on individual patient trends. 

There is also growing recognition that A1c, while invaluable, is only one piece of the glycemic puzzle. Metrics such as time-in-range, glycemic variability, and hypoglycemia burden are gaining prominence, particularly with the widespread adoption of CGM. The future of diabetes management will likely involve a more holistic approach that combines these metrics with A1c to guide care.

Conclusion: A More Immediate, More Effective Model of Care 

A1c testing in the exam room represents more than a technological advancement; it reflects a broader shift toward immediacy, integration, and patient-centered care. By eliminating delays and enabling real-time decision-making, point-of-care testing transforms A1c from a retrospective measure into a dynamic tool for guiding treatment. 

For primary care physicians, this shift offers a clear opportunity to improve the management of diabetes. With real-time data at their fingertips, clinicians can make more timely decisions, engage patients more effectively, and achieve better outcomes. As healthcare continues to evolve, the integration of point-of-care diagnostics into routine practice will play an increasingly important role in delivering high-quality, efficient, and responsive care.